The phase III SIRFLOX trial showed that selective internal radiation therapy delivered to liver metastases in patients with colorectal cancer, plus chemotherapy, improved local control, although median progression-free survival for the whole population was not affected.
Median progression-free survival of liver metastases was approximately 10 months overall in the study of 530 patients.
In patients with liver-only or liver-predominant metastases, however, median progression-free survival was improved by almost 8 months with the addition of selective internal radiation therapy.
Toxicity was slightly increased with the additional treatment modality. ■
A novel interventional approach to treating liver metastases associated with colorectal cancer improved control of liver metastases, according to the SIRFLOX study presented at the 2015 ASCO Annual Meeting.1
The addition of selective internal radiation therapy to first-line chemotherapy extended...